Form 8-K - Current report:
SEC Accession No. 0001634432-21-000015
Filing Date
2021-02-16
Accepted
2021-02-16 07:37:57
Documents
14
Period of Report
2021-02-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sbbp-20210210x8k.htm   iXBRL 8-K 51219
2 EX-99.1 sbbp-20210210ex991c058c5.htm EX-99.1 15809
3 GRAPHIC sbbp-20210210ex991c058c5001.jpg GRAPHIC 4922
  Complete submission text file 0001634432-21-000015.txt   202634

Data Files

Seq Description Document Type Size
4 EX-101.SCH sbbp-20210210.xsd EX-101.SCH 3004
5 EX-101.LAB sbbp-20210210_lab.xml EX-101.LAB 16053
6 EX-101.PRE sbbp-20210210_pre.xml EX-101.PRE 10387
7 EXTRACTED XBRL INSTANCE DOCUMENT sbbp-20210210x8k_htm.xml XML 4873
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

EIN.: 981130690 | State of Incorp.: L2
Type: 8-K | Act: 34 | File No.: 001-37569 | Film No.: 21632500
SIC: 2834 Pharmaceutical Preparations